Becton, Dickinson and Company (BDX) Bundle
An Overview of Becton, Dickinson and Company (BDX)
General Summary of Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX), founded in 1897, is a global leader in medical technology. The company specializes in the development, manufacture, and sale of medical devices, instrument systems, and reagents. Its product portfolio includes a wide range of offerings such as syringes, needles, blood collection systems, and diagnostic solutions. As of 2024, BDX reported total sales of approximately $20.2 billion, representing a 4.2% increase from the previous fiscal year.
Company's Financial Performance in the Latest Financial Reports
For the fiscal year ending September 30, 2024, BDX achieved a revenue of $20.178 billion, a substantial increase compared to $19.372 billion in 2023. This growth was driven by strong performance in its core segments:
- BD Medical: $10.074 billion
- BD Life Sciences: $5.191 billion
- BD Interventional: $4.980 billion
Operating income for the year was reported at $2.425 billion, up from $2.111 billion the previous year, indicating a 14.9% increase. The net income applicable to common shareholders reached $1.726 billion, compared to $1.424 billion in 2023, marking a 21.2% increase.
In terms of earnings per share, the diluted EPS from continuing operations was $5.93, which is a 20.0% increase from $4.94 in the previous year. The adjusted diluted EPS stood at $13.14, reflecting a 7.6% increase year-over-year.
Free cash flow also saw significant growth, increasing by 47.4% to $3.119 billion, compared to $2.116 billion in 2023.
Introduction to Company as a Leader in the Industry
BD is recognized as one of the largest global medical technology companies, serving healthcare providers and patients across the globe. The company is committed to advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. As of 2024, BD has continued to expand its portfolio through strategic acquisitions, including the Critical Care business from Edwards Lifesciences, enhancing its capabilities in advanced patient monitoring solutions.
The company has a workforce of over 70,000 employees and operates in virtually every country, reflecting its commitment to addressing global health challenges. BD's strong performance, innovative product offerings, and strategic initiatives reinforce its leadership position in the medical technology industry.
| Financial Metric | 2024 | 2023 | % Change |
|---|---|---|---|
| Total Revenues | $20.178 billion | $19.372 billion | 4.2% |
| Operating Income | $2.425 billion | $2.111 billion | 14.9% |
| Net Income | $1.726 billion | $1.424 billion | 21.2% |
| Diluted EPS | $5.93 | $4.94 | 20.0% |
| Free Cash Flow | $3.119 billion | $2.116 billion | 47.4% |
Mission Statement of Becton, Dickinson and Company (BDX)
Mission Statement of Becton, Dickinson and Company (BDX)
The mission statement of Becton, Dickinson and Company (BDX) encapsulates the company’s commitment to advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. This statement serves as a guiding principle for the organization, aligning its long-term goals with its core purpose of enhancing patient health and safety through innovation.
Core Component 1: Improving Medical Discovery
BDX is dedicated to advancing medical discovery through innovative technologies and solutions. The company invests significantly in research and development, with a reported R&D expenditure of $1.19 billion for fiscal year 2024, reflecting a 3.8% decrease from the previous year. This investment enables BDX to develop cutting-edge diagnostic tools and instruments that enhance the capabilities of laboratory scientists and researchers.
- The Integrated Diagnostic Solutions business unit contributed approximately $3.68 billion in revenue for fiscal year 2024, showcasing strong performance in specimen management and diagnostic testing.
- BD's acquisition of the Critical Care product group from Edwards Lifesciences expands its portfolio in monitoring technologies, indicating a strategic focus on enhancing medical discovery through advanced AI-enabled clinical decision tools.
Core Component 2: Enhancing Diagnostics
BDX’s mission emphasizes the importance of improving diagnostics to facilitate accurate disease detection and treatment. The company’s Integrated Diagnostic Solutions have shown robust growth, driven by strong demand for innovative diagnostic assays. For instance, the BD Onclarity™ HPV Assay received Health Canada approval, reflecting BDX's commitment to advancing diagnostic capabilities.
- In fiscal year 2024, the BD Life Sciences segment reported revenues of approximately $5.19 billion, highlighting the significant contribution of diagnostic solutions to overall performance.
- The introduction of new robotics solutions for single-cell research further underscores BDX’s commitment to enhancing diagnostics and laboratory efficiency.
Core Component 3: Delivering Care
Delivering high-quality care is a fundamental aspect of BDX’s mission. The company focuses on creating innovative solutions that improve patient safety and care delivery. In fiscal year 2024, BDX reported a total revenue of $20.18 billion, marking a 4.2% increase compared to the previous year.
- BD Medical’s revenue reached approximately $10.07 billion, driven by strong growth in medication delivery solutions and patient monitoring systems.
- The BD HealthSight™ Diversion Management software, utilizing advanced AI to detect controlled substance diversion, exemplifies BDX's approach to improving safety and efficiency in healthcare settings.
| Financial Metric | FY 2023 | FY 2024 | % Change |
|---|---|---|---|
| Total Revenue | $19.37 billion | $20.18 billion | 4.2% |
| R&D Expenditure | $1.24 billion | $1.19 billion | -3.8% |
| BD Life Sciences Revenue | $5.13 billion | $5.19 billion | 1.1% |
| BD Medical Revenue | $9.50 billion | $10.07 billion | 6.0% |
Through its mission statement, BDX articulates a clear vision for the future, centered on innovation, quality, and patient care. The organization’s focus on improving medical discovery, enhancing diagnostics, and delivering care reflects its commitment to addressing some of the most pressing health challenges globally.
Vision Statement of Becton, Dickinson and Company (BDX)
Vision Statement Overview
The vision statement of Becton, Dickinson and Company (BDX) emphasizes their commitment to advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. This vision is supported by their strategy to leverage significant technological advancements in healthcare.
Commitment to Innovation
In 2024, BD has focused on integrating advanced technologies such as biologics, artificial intelligence (AI), and automation into their solutions. This commitment is evident in their recent acquisition of Edwards Lifesciences' Critical Care product group, which enhances BD's capabilities in smart connected care solutions.
| Component | Details |
|---|---|
| Acquisition | Edwards Lifesciences' Critical Care product group |
| Technological Focus | Biologics, AI, Automation |
| Impact | Enhanced patient care through innovative solutions |
Global Reach and Collaboration
BD operates in virtually every country, collaborating with healthcare organizations to address pressing global health challenges. This global presence allows BD to enhance healthcare outcomes, lower costs, and improve efficiency by tailoring solutions to local needs.
Financial Performance and Growth Strategy
For the fiscal year ending September 30, 2024, BD reported revenues of $20.2 billion, marking a 4.2% increase from the previous year. The growth strategy focuses on shifting the portfolio into higher-growth areas through innovation and strategic acquisitions.
| Financial Metric | Value |
|---|---|
| Total Revenue FY24 | $20.2 billion |
| Revenue Growth | 4.2% |
| GAAP Diluted EPS | $5.93 |
| Adjusted Diluted EPS | $13.14 |
Focus on Healthcare Professionals
BD's vision includes a strong emphasis on supporting healthcare professionals by developing innovative technologies and solutions that improve clinical processes. This approach is designed to enhance the safety and efficiency of care delivery, ultimately benefiting patients and healthcare providers alike.
Future Outlook
Looking forward, BD has provided guidance for FY25 with expected revenue growth of 8.9% to 9.4%. This outlook reflects the company's ambition to continue creating value for shareholders through operational excellence and strategic investments in high-growth areas.
| FY25 Outlook | Projected Growth |
|---|---|
| Revenue Growth | 8.9% to 9.4% |
| Adjusted Diluted EPS | $14.25 to $14.60 |
Core Values of Becton, Dickinson and Company (BDX)
Integrity
The core value of Integrity at Becton, Dickinson and Company (BD) emphasizes the importance of honesty and ethical behavior in all business dealings. This commitment ensures trust among stakeholders and fosters a culture of accountability.
In 2024, BD has demonstrated its integrity through various initiatives, including transparency in its financial reporting and adherence to regulatory standards. For instance, BD reported a net income from continuing operations of $1.726 billion for the fiscal year 2024, which reflects a 12.8% increase from the previous year. The company also actively addresses compliance issues, as evidenced by its $175 million charge for an estimated liability related to an SEC investigation regarding its infusion pumps.
Innovation
Innovation is central to BD's mission, driving the development of advanced medical technologies and solutions. The company invests significantly in research and development to enhance healthcare delivery.
In fiscal 2024, BD's R&D expense was $1.190 billion, showcasing its dedication to innovation. The launch of the BD® Intraosseous Vascular Access System is a recent example, designed to provide rapid access for medication delivery in emergencies. Additionally, the acquisition of Edwards Lifesciences’ Critical Care product group has expanded BD’s capabilities in smart connected care solutions, integrating AI-enabled clinical decision tools.
Collaboration
The value of Collaboration at BD highlights the importance of teamwork and partnerships in achieving shared goals. This approach enhances the effectiveness of its operations and customer service.
BD has established numerous partnerships with healthcare providers and organizations to improve clinical outcomes. For example, the company’s BD HealthSight™ software utilizes advanced AI to detect controlled substance diversion in operating rooms, reflecting collaborative efforts with healthcare professionals to ensure patient safety. Furthermore, BD's presence in over 190 countries facilitates global collaboration in addressing health challenges.
Customer Focus
Customer Focus ensures that BD prioritizes the needs and experiences of its customers in all aspects of its operations. This value drives the company to deliver high-quality products and services that meet the evolving demands of healthcare providers.
In 2024, BD reported a revenue increase to $20.178 billion, with a 4.2% growth attributed to strong customer demand across its segments. The BD Alaris™ infusion system continues to receive positive feedback for enhancing patient safety and improving clinical workflows. BD's commitment to customer satisfaction is further evidenced by its recognition as one of the 100 Best Corporate Citizens of 2024, where it ranked second in the healthcare equipment and services industry.
Diversity and Inclusion
Diversity and Inclusion are integral to BD's corporate culture, promoting a workplace where all employees feel valued and respected. This commitment enhances creativity and innovation within the organization.
In 2024, BD was recognized as a Best Place to Work for Disability Inclusion for the sixth consecutive year, achieving a top score on the Disability Equality Index. The company actively promotes diversity through various initiatives and training programs aimed at fostering an inclusive environment for its over 70,000 employees worldwide.
| Core Value | Key Initiatives | Financial Impact |
|---|---|---|
| Integrity | Transparency in reporting, compliance with regulations | Net income of $1.726 billion (FY 2024) |
| Innovation | Investment in R&D, new product launches | R&D expense of $1.190 billion (FY 2024) |
| Collaboration | Partnerships with healthcare providers, global presence | Revenue growth to $20.178 billion (FY 2024) |
| Customer Focus | High-quality products, customer satisfaction initiatives | Ranked among the 100 Best Corporate Citizens (2024) |
| Diversity and Inclusion | Disability inclusion programs, employee training | Top score on Disability Equality Index (2024) |
Becton, Dickinson and Company (BDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Becton, Dickinson and Company (BDX) Financial Statements – Access the full quarterly financial statements for Q4 2024 to get an in-depth view of Becton, Dickinson and Company (BDX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Becton, Dickinson and Company (BDX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.